GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJY) » Definitions » Additional Paid-In Capital

UCB (UCBJY) Additional Paid-In Capital : $2,185 Mil(As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is UCB Additional Paid-In Capital?


UCB's quarterly additional paid-in capital increased from Jun. 2023 ($2,199 Mil) to Dec. 2023 ($2,214 Mil) but then stayed the same from Dec. 2023 ($2,214 Mil) to Jun. 2024 ($2,185 Mil).

UCB's annual additional paid-in capital declined from Dec. 2021 ($2,294 Mil) to Dec. 2022 ($2,150 Mil) but then increased from Dec. 2022 ($2,150 Mil) to Dec. 2023 ($2,214 Mil).

UCB Additional Paid-In Capital Historical Data

The historical data trend for UCB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Additional Paid-In Capital Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2,469.59 2,293.79 2,150.42 2,213.74

UCB Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,145.88 2,150.42 2,199.35 2,213.74 2,185.15

UCB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

UCB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of UCB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJY) » Definitions » Additional Paid-In Capital
Comparable Companies
XBRU:ARGX XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX REGN ASX:CSL XKRX:207940 ALNY XKRX:068270 BNTX BGNE MRNA SMMT UTHR OCSE:GMAB XKRX:196170
Traded in Other Exchanges
UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
Website
https://www.ucb.com
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).